Why the study?
The isolated and joint effects of early menopause and high-sensitivity cardiac troponin T elevation on heart failure incidence in postmenopausal women were not established.
Does early menopause and/or hs-cTnT elevation increase the risk of incident heart failure in postmenopausal women?
Cohort (n=2,276)
Yes
Does early menopause and/or hs-cTnT elevation increase the risk of incident heart failure in postmenopausal women?
Early menopause is an independent risk factor for incident heart failure in older postmenopausal women, even in the absence of elevated hs-cTnT, after adjusting for traditional risk factors.
Answers are grounded in this paper and cite their sources.
May inform HF risk stratification in postmenopausal women; hypothesis-generating for causal mechanisms and prevention trials.
OBJECTIVE: We investigated isolated and joint effects of early menopause (occurrence before 45 y of age) and high-sensitivity cardiac troponin T elevation (hs-cTnT ≥ 14 ng/L) on heart failure (HF) incidence in postmenopausal women. METHODS: We included 2,276 postmenopausal women, aged 67-90 years, with hs-cTnT measurements and without prevalent HF from the Atherosclerosis Risk in Communities study Visit 5 (2011-2013). Women were categorized according to early menopause and hs-cTnT group. Cox proportional hazards models were used for analysis. RESULTS: Over a median follow-up of 5.5 years, we observed 104 HF events. The incidence rates of HF were greater in women with hs-cTnT elevation when compared to those without hs-cTnT elevation. In unadjusted analysis, the hazard ratios for incident HF were threefold greater in women with hs-cTnT elevation, with or without early menopause, (3.03 [95% CI, 1.59-5.77]) and (3.29 [95% CI, 2.08-5.21]), respectively, but not significantly greater in women with early menopause without hs-cTnT elevation, when compared to women with neither early menopause nor hs-cTnT elevation at Visit 5. After adjusting for HF risk factors and NT-pro B-type natriuretic peptide, these associations were attenuated and became nonsignificant for women with hs-cTnT elevation, but became stronger and significant for women with early menopause without hs-cTnT elevation (2.39 [95% CI, 1.28-4.46]). CONCLUSIONS: Irrespective of early menopause status, hs-cTnT elevation is associated with greater HF incidence but this association is partially explained by HF risk factors. Even in the absence of hs-cTnT elevation, early menopause is significantly associated with HF incidence after accounting for HF risk factors.
No takes yet. Share an insight, caveat, or question.
Ebong et al. (2021) conducted a cohort in heart failure incidence in postmenopausal women (n=2,276). Early menopause and/or high-sensitivity cardiac troponin T (hs-cTnT) elevation vs. Women with neither early menopause nor hs-cTnT elevation was evaluated on Incident heart failure (HR 2.39, 95% CI 1.28-4.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: